Compare PNTG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | COLL |
|---|---|---|
| Founded | 2019 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2019 | 2015 |
| Metric | PNTG | COLL |
|---|---|---|
| Price | $40.31 | $21.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $46.83 | ★ $49.00 |
| AVG Volume (30 Days) | 384.7K | ★ 772.3K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $947,705,000.00 | $780,567,000.00 |
| Revenue This Year | $24.90 | $6.73 |
| Revenue Next Year | $7.79 | $1.37 |
| P/E Ratio | $81.94 | ★ N/A |
| Revenue Growth | ★ 36.31 | 23.62 |
| 52 Week Low | $22.26 | $21.43 |
| 52 Week High | $42.74 | $50.79 |
| Indicator | PNTG | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 31.38 |
| Support Level | $37.81 | $21.54 |
| Resistance Level | $41.07 | $23.69 |
| Average True Range (ATR) | 1.38 | 0.63 |
| MACD | 0.02 | 0.22 |
| Stochastic Oscillator | 64.36 | 23.56 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.